Imiquimod
This topical immune response modifier is used to treat certain viral skin conditions including genital warts (condyloma acuminata), superficial basal cell carcinoma, and actinic keratoses. It works by stimulating the local immune system to produce interferon and other cytokines, which attack the abnormal or virus-infected cells. It is applied directly to the skin and should not be used internally.
Молекулярная масса
240,3000 g/mol
LogP
2,60
TPSA
56,70 Ų
Правило пяти Липинского
Соответствует
Терапевтические области
Механизм действия
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D Структура
Cite this structure
Embed this structure
SMILES
CC(C)Cn1cnc2c(N)nc3ccccc3c21
InChI
InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
Molecular Formula
C14H16N4
HBD / HBA
1 / 3
Вращаемые Связи
2
Тяжёлые Атомы
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
This topical immune response modifier is used to treat certain viral skin conditions including genital warts (condyloma acuminata), superficial basal cell carcinoma, and actinic keratoses. It works by stimulating the local immune system to produce interferon and other cytokines, which attack the abnormal or virus-infected cells. It is applied directly to the skin and should not be used internally.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Imiquimod is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1282. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 57469. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="imiquimod"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/imiquimod/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/imiquimod/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/imiquimod/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="imiquimod"></drugfyi-drug>